HEALTHCARE REALTY TRUST INCORPORATED
In the published model solve dated 2026-Q2, anchored at $21.84, HEALTHCARE REALTY TRUST INCORPORATED (HR) is priced for +9.1% FFO growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Healthcare Realty owns medical office buildings, mostly on or near hospital campuses, and the single metric that drives it is same-store cash net operating income, which grew 6.9% in Q1 2026 on the back of a record 2 million square feet of leases signed in the quarter. [Source: Q1 2026 earnings call] • The biggest risk is leverage paired with tenant dependence: net debt runs nearly 13 times funds from operations, and the 10-K warns that the viability of the health systems that anchor its build
Is HR overvalued? See what's priced in →
427 institutional managers reported holding HR in 13F filings for the quarter ended 2026-03-31. 57 opened new positions that quarter. Held by BlackRock, Cohen & Steers, Vanguard Group, among others. On the short side, 17.4M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (3.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
HR's share count grew 58.8% over the past five years even with $619.96M spent on repurchases. It pays a dividend, and has paid one every year in our records (16 and counting); the current rate is $1.10 a share annually. Cash returned over the past three years: $1.16B in dividends and $614.88M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at HR over the trailing three years: 2023: 1 buy totaling $539k; 2024: 14 buys totaling $1.38M; 2025: 2 buys totaling $201k; 2026: 2 buys totaling $181k. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
HR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | -1.6% | -3.5% |
| 2023-08-09 | -6.0% | -18.8% |
| 2023-11-04 | -0.5% | +13.2% |
| 2024-05-08 | +2.1% | +10.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
HR's latest 8-K filings: 2026-07-31 (items 8.01, 9.01); 2026-07-30 (items 2.02, 7.01, 9.01); 2026-05-20 (items 5.07); 2026-05-19 (items 1.01, 2.03, 9.01); 2026-05-07 (items 1.01, 2.03, 3.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.